Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New findings about protection against pneumococcal disease

31.03.2005


Findings hoped to spur the development of an improved vaccine



Since 2000, U.S. infants have been routinely immunized against pneumococcal (Streptococcus pneumoniae) infection. Now, Boston researchers have made a surprising discovery about natural immunity to pneumococcus. Two related studies, led by Dr. Richard Malley of the Children’s Hospital Boston Division of Infectious Diseases and Dr. Marc Lipsitch of the Harvard School of Public Health, suggest that natural protection from pneumococcal disease may derive from some previously unrecognized immune mechanism, which could possibly be exploited for a new vaccine. The latest study appears in the current (March 29) issue of the Proceedings of the National Academy of Sciences.

In the U.S., before the advent of the pneumococcal conjugate vaccine, known as Prevnar, S. pneumoniae caused more than 7 million ear infections each year, half a million episodes of bacterial pneumonia, and life-threatening cases of meningitis and bacteremia. Prevnar is made up of material from the outer capsule of each of the seven pneumococcal strains most common in the U.S. This material triggers recipients’ immune systems to produce so-called anticapsular antibodies specific to those strains. However, Prevnar doesn’t work against many pneumococcal strains in the developing world, where pneumococcus kills nearly 1 million children annually, and it is expensive and difficult to manufacture, leading to chronic shortages. Moreover, in several studies, use of pneumococcal conjugate vaccines caused non-vaccine strains to become more common, raising concerns that Prevnar could eventually become ineffective even in the U.S. Of 90 known pneumococcal strains, Prevnar only covers seven.


Lipsitch and Malley first conducted epidemiologic studies in unvaccinated toddlers in the U.S., Israel, and Finland. As they reported in January in the online journal PLoS Medicine, the incidence of invasive disease from almost all pneumococcal strains fell by nearly half between 1 and 2 years of age. Yet, anti-capsular antibody concentrations increased only slightly, suggesting that a mechanism other than antibody to the pathogen’s outer capsule may be conferring natural protection against pneumococcal disease.

What then might provide this protection? Looking at the first step of pneumococcal disease, colonization of the nose and throat, Malley and Lipsitch were able to elicit long-lasting immunity to pneumococcus in mice independently of any antibodies. In the current (March 29) Proceedings of the National Academy of Science, they report that when mice were exposed to live pneumococci, or to a whole-cell vaccine developed in Malley’s lab, they were highly immune to pneumococcal colonization -- even if they were genetically unable to make antibodies. Moreover, mice exposed to a single pneumococcal strain became immune not just to that strain, but to others. The immunity appeared to arise from an effect on the immune system’s CD4+ T-cells, since mice that lacked these cells did not develop immunity.

"Textbooks say that naturally-acquired protection against pneumococcal disease depends on the development of antibody against the capsule of the bacterium," says Malley, who is also an assistant professor in pediatrics at Harvard Medical School. "We were surprised to find that protection was independent of not only antibody to the capsule, but also antibody of any specificity."

Overall, their findings suggest that while antibodies are sufficient for protection against pneumococcal disease, they may not represent the natural mechanism of protection.

"An interesting observation is that HIV-infected children, whose CD4+ cells are depleted by the virus, are at about a 200-fold higher risk for pneumococcal disease," Malley adds. "Our experiments in mice may provide an explanation for that vulnerability."

The whole-cell vaccine developed by Malley’s lab could potentially protect against all pneumococcal strains, Malley says. The vaccine, made of killed pneumococcal cells, was shown to prevent colonization and invasive disease when given to animals in the form of nose drops. Malley believes the vaccine stimulates CD4+ T-cells to identify components of pneumococcus that are identical in every strain and to provide protection at the earliest stage of infection, when pneumococcus is colonizing the nasal passages.

The whole-cell vaccine, or a derivative of it, would be a boon for the developing world, because it is inexpensive, covers all pneumococcal strains, and does not require refrigeration. Malley and colleagues are now working to define precisely how the whole-cell vaccine works immunologically, and determine what parts of the killed bacterium provide the actual protection. The ultimate goal is to test the vaccine in adult volunteers, and eventually in children.

Susan Craig | EurekAlert!
Further information:
http://www.childrens.harvard.edu

More articles from Health and Medicine:

nachricht Fast-tracking T cell therapies with immune-mimicking biomaterials
16.01.2018 | Wyss Institute for Biologically Inspired Engineering at Harvard

nachricht Dengue takes low and slow approach to replication
12.01.2018 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Novel 3-D printing technique yields high-performance composites

16.01.2018 | Materials Sciences

New application for acoustics helps estimate marine life populations

16.01.2018 | Life Sciences

Fast-tracking T cell therapies with immune-mimicking biomaterials

16.01.2018 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>